Related Experiment Videos
Mitogen-activated protein kinase inhibitor, PD98059, inhibits rat retinal pigment epithelial cell replication by cell
Katsuhiro Yamaguchi1, Hiroshi Tomita, Eriko Sugano
1Department of Ophthalmology, Tohoku University School of Medicine, Sendai, Japan.
Purpose:
To investigate the effect of PD98059, a mitogen-activated protein kinase (MAPK) inhibitor, on the replication of rat cultured retinal pigment epithelial (RPE) cells.
Methods:
Growth-phase rat RPE cells were exposed to various concentrations of PD98059 in serum-free F12 medium containing 0.1% dimethyl sulfoxide. Cell proliferation was assessed by cell counts using a hemocytometer. Cell viability was tested by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay at 24 hours after PD98059 application. Hoechst 33552 and propidium iodide staining were used to assess nuclear morphology. Immunostaining with Ki67 antibody was used for cell cycle analysis because the staining patterns produced on cells are characteristic depending on their position within the cell cycle.
Results:
PD98059 inhibited cellular proliferation of cultured rat RPE cells in a dose-dependent manner but did not induce cell death. Twenty-four hours after the application of PD98059, cultured RPE cells were not immunopositive for Ki67, indicating that their cell cycle was arrested in the G0/G1 phase.
Conclusion:
These results demonstrated that MAPK inhibition arrested cell cycle progression of rat cultured RPE cells at the G0/G1 phase. The pharmacological induction of cell cycle arrest could be a new approach to inhibit cellular proliferation in such conditions as proliferative vitreoretinopathy.
Insights
Mitogen-activated protein kinase (MAPK) inhibition with PD98059 arrested cell cycle progression in rat retinal pigment epithelial (RPE) cells at the G0/G1 phase, offering a potential therapeutic strategy for proliferative vitreoretinopathy.
Area of Science:
- Cell Biology
- Pharmacology
- Ophthalmology
Background:
- Retinal pigment epithelial (RPE) cells play a crucial role in retinal health.
- Uncontrolled RPE cell proliferation is implicated in conditions like proliferative vitreoretinopathy.
- Understanding mechanisms to control RPE cell proliferation is vital for therapeutic development.
Purpose of the Study:
- To investigate the effect of PD98059, a MAPK inhibitor, on the proliferation of cultured rat RPE cells.
- To determine if PD98059 affects RPE cell viability and cell cycle progression.
Main Methods:
- Cultured rat RPE cells were treated with varying concentrations of PD98059.
- Cell proliferation was quantified using cell counts.
- Cell viability was assessed using a non-radioactive proliferation assay.
- Nuclear morphology and cell cycle phase were analyzed via Hoechst/propidium iodide staining and Ki67 immunostaining.
Main Results:
- PD98059 inhibited RPE cell proliferation in a dose-dependent manner.
- No significant cell death was observed following PD98059 treatment.
- Ki67 staining indicated cell cycle arrest at the G0/G1 phase 24 hours post-treatment.
Conclusions:
- MAPK inhibition by PD98059 effectively arrests the cell cycle of rat RPE cells at the G0/G1 phase.
- Pharmacological induction of cell cycle arrest presents a novel therapeutic approach for inhibiting RPE cell proliferation.
- This strategy holds promise for treating conditions such as proliferative vitreoretinopathy.